Background

The p64MW HPC and p48MW HPC flow diverters have reduced thrombogenicity due to hydrophilic coating. The purpose of this study was to evaluate its safety and efficacy in Mongolian patients under single antiplatelet therapy (SAPT) with prasugrel.

Materials and methods

We performed a retrospective review of patients enrolled into our prospectively maintained database to identify all patients treated with either the p48MW HPC or p64MW HPC under SAPT. We recorded baseline demographics, aneurysm size and location, procedural complications, angiographic and clinical results.

Results

24 patients, (female = 21, 87.5%), age 48.2 ± 11.6 years (range 25–63) underwent treatment of 30 aneurysms with either p64MW HPC or p48MW HPC. All aneurysms were saccular with dome width 8.2 ± 6.5 (range 1.6–26.0 mm) and dome height 7.6 ± 6.7 (range 1.6–30.0 mm). None of the aneurysms were previously treated. The average PRU was 54.6 ± 31.2 (range 1–127) on pre-operative VerifyNow testing. Angiographic follow-up was available for 13 patients (17 aneurysms), 183 ± 36 days post-procedure, at which point 64.7% of aneurysms (n = 11/17) were completely occluded and 11.8% (n = 2/17) had only neck remnants resulting in 76.5% of aneurysms being adequately occluded A single intra-operative complication (4.2%) occurred however all patients were mRS ≤1 at last follow-up. There were two post-operative complications neither of which resulted in permanent neurological morbidity. There were no instances of post-operative aneurysmal rupture or delayed parenchymal haemorrhage. The overall mortality was 0%.

Conclusion

The efficacy and safety of p64MW HPC coated devices under SAPT is similar to uncoated flow diverters that require DAPT.

中文翻译：

---

p48MW HPC 和 p64MW HPC 分流器在前循环动脉瘤中使用单一抗血小板治疗的早期临床经验

背景

由于亲水涂层，p64MW HPC 和 p48MW HPC 分流器减少了血栓形成。本研究的目的是评估其在接受普拉格雷单次抗血小板治疗 (SAPT) 的蒙古患者中的安全性和有效性。

材料和方法

我们对纳入我们前瞻性维护的数据库的患者进行了回顾性审查，以确定所有在 SAPT 下接受 p48MW HPC 或 p64MW HPC 治疗的患者。我们记录了基线人口统计学、动脉瘤大小和位置、手术并发症、血管造影和临床结果。

结果

24 名患者（女性 = 21，87.5%），年龄 48.2 ± 11.6 岁（范围 25-63）接受了 p64MW HPC 或 p48MW HPC 治疗 30 个动脉瘤。所有动脉瘤均为囊状，圆顶宽度为 8.2 ± 6.5（范围 1.6–26.0 mm），圆顶高度为 7.6 ± 6.7（范围 1.6–30.0 mm）。之前没有任何动脉瘤被治疗过。术前 VerifyNow 测试的平均 PRU 为 54.6 ± 31.2（范围 1-127）。13 名患者（17 个动脉瘤）在术后 183 ± 36 天进行了血管造影随访，此时 64.7% 的动脉瘤（n = 11/17）完全闭塞，11.8%（n = 2/17）有仅颈部残余导致 76.5% 的动脉瘤被充分闭塞 有两种术后并发症均未导致永久性神经系统疾病。没有术后动脉瘤破裂或迟发性实质出血的病例。总死亡率为0%。

结论

SAPT 下 p64MW HPC 涂层设备的功效和安全性与需要 DAPT 的未涂层分流器相似。